

IMPORTANT INFORMATION: GLYPRESSIN® (terlipressin acetate) upcoming name/code change

Dear Healthcare Professional,

As of the 1st of May 2024, Ferring will be removing the brand name GLYPRESSIN® (terlipressin acetate) from our 1 mg powder and solvent for solution for injection vials, and our 0.12 mg/ml solution for injection ampoules. The product will be sold under its generic name, terlipressin acetate, from May 2024.

We want to assure you that this change will not impact the quality or efficacy of our terlipressin acetate products. There will be no alterations to the package size, and any modifications to the packages' look and feel are minimal as you can see below.

| Product names | Pack Image | PIP code | Date |
|--|---|----------|-----------------|
| <p>Previous: GLYPRESSIN® injection 1mg powder and solvent for solution for injection vials</p> |  | 03467719 | End: April 2024 |
| <p>New: Terlipressin acetate 1mg powder and solvent for solution for injection vials</p> |  | 127-0974 | Start: May 2024 |
| <p>Previous: GLYPRESSIN® 0.12mg/ml solution for injection ampoules</p> |  | 00178400 | End: April 2024 |
| <p>New: Terlipressin acetate 0.12mg/ml solution for injection ampoules</p> |  | 426-2812 | Start: May 2024 |

We kindly request that once the new product becomes available, you promptly place an order for the terlipressin acetate products using the new PIP Codes. This will ensure that there are no delays or issues in dispensing this product to your patients.

If you require any further information or assistance with updating your system, please do not hesitate to contact us.

Thank you for your understanding and attention to this matter.

Sincerely,



General Manager Ferring UK & Ireland

Commerical-related questions should be directed to:

Ferring Customer Services

0800 1114125

Customer.services@ferring.com

Medical related questions should be directed to:

Ferring Medical

0800 1114126

Medical.uk@ferring.com